Personalized, Persistent, Powerful: mRNA Takes On Breast Cancer

BioNTech's personalized mRNA vaccine kept 11 of 14 aggressive breast cancer patients relapse-free for up to six years

30 Mar 2026

BioNTech has reported a significant result in personalised cancer medicine, with a customised mRNA vaccine holding aggressive breast cancer at bay for up to six years in the majority of patients enrolled in an early-stage trial. The findings, published in Nature on 18 February 2026, mark one of the longest sustained immune responses recorded in personalised oncology.

The TNBC-MERIT Phase I trial, conducted at medical centres in Germany and Sweden, enrolled 14 patients with triple-negative breast cancer, a form of the disease that lacks the hormonal and protein markers that make many other breast cancers treatable and that carries a high risk of rapid recurrence within three years of surgery. Eleven patients remained relapse-free across the observation period.

Each vaccine was constructed individually. Surgeons removed tumour tissue, sequenced its DNA, and identified up to 20 mutations unique to that patient's cancer. BioNTech's team in Mainz encoded those mutations into a personalised mRNA construct, delivered intravenously via lipid nanoparticles designed to activate the immune system's dendritic cells. Nearly all patients mounted strong T-cell responses against multiple cancer targets.

The durability of those responses proved notable. Neoantigen-specific T cells remained detectable and functionally active for years after vaccination, without booster doses. Researchers identified two long-lived immune cell populations: active cytotoxic cells capable of targeting cancer, and a stem-like memory population able to self-renew, maintaining immune vigilance after treatment ended.

The three relapses in the study yielded important observations. In one case, the cancer evolved to evade immune detection. In another, a genetically distinct second tumour emerged that the vaccine had not been designed to target. A third patient, who had shown a weak initial response, subsequently achieved complete remission following anti-PD-1 therapy, raising the possibility that the vaccine may sensitise patients to follow-on immunotherapy.

BioNTech's personalised mRNA platform has previously shown early promise in melanoma and pancreatic cancer. Whether the durability observed in this small cohort holds across larger, controlled trials remains the central question as the company prepares to expand its programme.